Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) Stock Overview
Explore Summit Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
12B
P/E Ratio
-11.16
EPS (TTM)
$-1.44
ROE
-2.97%
SMMT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Summit Therapeutics Inc. (SMMT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 47.49, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $22.16.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -11.16 and a market capitalization of 12B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.